Diligence memo · auto-generated · as of July 2, 2026

Aliva Biopharmaceuticals, LLC

Aliva Biopharmaceuticals, LLC looks over-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Aliva Biopharmaceuticals, LLC operates in Biotechnology, based in PASADENA.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Aliva Biopharmaceuticals, LLC has raised $13M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $13M on 2009-12-30.

Most recent recorded round closed around 2009-12-30.

Valuation (modeled)modeled

Provath models Aliva Biopharmaceuticals, LLC at approximately $465M (range $14M–$2.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 1.57× the median modeled value of Series A Biotechnology companies in 2007–2009 (35 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Last raise 16.5 yr ago; this sector typically re-raises about every 14 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 60% of Biotechnology peers (4293 compared).

Modeled value ranks above 82% of those peers.

Closest niche peers: Complete Genomics Inc, BioTrove, Inc., Molecular Biometrics Inc, Bioimagene Inc, CircuLite Inc.

Peoplefiled

1 named person on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.